- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05972616
Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion
A Single-center Review of the Performance of Induce Biologics NMP™ in Patients Who Have Undergone Interbody Fusion for Degenerative Disease of the Lumbar Spine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study involves a retrospective review of patients' medical records and prospective collection of CT scans, X-rays, and patient centered outcome questionnaires.
The study population will include up to 135 patients of the Spine Institute of Louisiana (SIL) who have been treated with Induce Biologics NMP™ during a lumbar interbody fusion. All subjects who meet all inclusion criteria and do not meet any exclusion criteria will be included in the study.
There will be a single Prospective Visit in this study. This visit will be scheduled at the 12-month (± 2 mo) post-surgery time point.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Spine Institute of Louisiana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have clinical or radiological evidence of degenerative disc disease of the lumbar spine.
- Have been treated with Induce Biologics NMP™ during a lumbar spinal fusion procedure.
- Be at least 18 years of age.
- Have current contact information.
- Be willing and able to provide written Informed Consent for the prospective part of study participation.
- Be willing and able to undergo a CT-scan and X-rays.
- Be willing and able to complete patient centered outcome questionnaires.
Exclusion Criteria:
- Currently imprisoned.
- Currently experiencing major mental illness (psychosis, schizophrenia, major affective disorder) which in the opinion of the investigator may indicate that the symptoms are psychological rather than of physical origin.
- X-rays or CT-scan are contraindicated.
- Any previous lumbar fusion or arthroplasty surgery at the index level(s)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NMP
Have clinical or radiological evidence of degenerative disc disease of the lumbar spine. Have been treated with NMP™ during a lumbar spinal fusion procedure. |
human bone allograft
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic fusion rate
Time Frame: 12-months post-surgery
|
CT scans will be graded from 0 (no boney ingrowth) to 3 (complete bridging) and A (no evidence of supplemental fixation failure) or B (evidence of supplemental fixation failure). Fusion will be defined as a CT grade of 3A with less than 3 degrees of motion at the index level on flexion and extension x-rays. |
12-months post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disability score assessed by Oswestry Disability Index
Time Frame: Baseline to 12 months post-operative
|
Disability will be assessed using the Oswestry Disability Index (ODI).
ODI is a questionnaire to collect a patient's responses to questions about perceived function (disability) in 10 everyday activities in patients with acute or chronic low back pain.
Each question consists of 6 statements about 1 activity which are scored from 0 to 5. With 0 indicating the least disability and 5 the greatest.
The scores are combined to a single score from 0 (no disability) to 50 (completely disabled)
|
Baseline to 12 months post-operative
|
Change in disability score assessed by the 12-Item Short Form Survey version 2
Time Frame: Baseline to 12 months post-operative
|
Disability will be assessed by the 12-Item Short Form Survey version 2 (SF-12v2). The SF-12 is is a questionnaire to collect a patient's responses to 12 questions about their physical and mental health. It is often used as a quality of life measure. Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The minimum score for MCS-12 is 3.2 and the maximum score is 77.9. The minimum score for PCS-12 is 9.9 and the maximum score 76.0. The lower the score the worse the health. |
Baseline to 12 months post-operative
|
Change in pain score - for the Back
Time Frame: Baseline to 12 months post-operative
|
Pain will be assessed by Visual Analogue Scale (VAS) for back pain.
VAS is a straight horizontal line of fixed length.
The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time.
The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.
The minimum score is 0 and the maximum score is 100.
The larger the number the worse the pain being experienced.
|
Baseline to 12 months post-operative
|
Change in pain score - for the Left Leg
Time Frame: Baseline to 12 months post-operative
|
Pain will be assessed by Visual Analogue Scale (VAS) for left leg pain.
VAS is a straight horizontal line of fixed length.
The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time.
The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.The minimum score is 0 and the maximum score is 100.
The larger the number the worse the pain being experienced.
|
Baseline to 12 months post-operative
|
Change in pain score - for the Right Leg
Time Frame: Baseline to 12 months post-operative
|
Pain will be assessed by Visual Analogue Scale (VAS) for right leg pain.
VAS is a straight horizontal line of fixed length.
The ends are defined as the extreme limits of the pain to be measured from the left (no pain) to the right (worst pain imaginable) and the patient marks on the line how much pain they are experiencing at that time.
The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.
The minimum score is 0 and the maximum score is 100.
The larger the number the worse the pain being experienced.
|
Baseline to 12 months post-operative
|
Adverse Events (AE) related to NMP
Time Frame: Baseline to 12 months post-operative
|
All Adverse Events (AE) will be documented in detail and followed to a satisfactory resolution regardless of the cause. The intensity of the adverse event is determined by the investigator using the following definitions: Mild: The AE is commonly asymptomatic or causes minimal symptoms and does not require any active intervention. Moderate: The AE causes discomfort and requires treatment but does not pose any significant or permanent risk to harm the subject. It may or may not require any intervention. Severe: Incapacitating with inability to perform usual activities. It is a definite hazard to health, reduced life expectancy, death, or life threatening, necessitates medical or surgical intervention to preclude permanent disability. The number of mild, moderate and severe AE determined to be related to NMP™ will be collected and reported. |
Baseline to 12 months post-operative
|
Change in neurologic status
Time Frame: Baseline to 12 months post-operative
|
Neurologic status will be assessed using a grading scale during a physical exam.
The patient will be scored by a clinician as to motor strength (0 to 5 paralysis to normal), sensory function based on response to touch and pin prick (0 absent, 1 numbness, 2 normal, 3 hypersensitive) and reflexes (0 absent, 1 diminished, 2 normal, 3 hyperactive, 4 hyperactive with clonus).
|
Baseline to 12 months post-operative
|
Revisions/reoperations
Time Frame: Baseline to 12 months post-operative
|
number of revisions or reoperations performed will be collected and reported.
|
Baseline to 12 months post-operative
|
Duration of hospitalization
Time Frame: time of surgery to time of discharge, assessed up to 12 months
|
number of days in hospital post-operation will be collected and reported.
|
time of surgery to time of discharge, assessed up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierce Nunley, MD, Spine Institute of Louisiana
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIL-2023-NMP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
Clinical Trials on Natural Matrix Protein (NMP)
-
Induce Biologics USA Inc.Not yet recruitingDegenerative Disc Disease | Spinal Stenosis | Degenerative SpondylolisthesisUnited States
-
T.C. Dumlupınar ÜniversitesiCompletedBone Density Increased | Osseointegration Failure of Dental ImplantTurkey
-
Kaiser PermanenteCompletedMalnutrition | Hypoalbuminemia | Peritoneal Dialysis ComplicationUnited States
-
University of PadovaCompletedHormone | Insulin Tolerance | Aminoacidaemia
-
Lawson Health Research InstituteCompleted
-
Aziyo Biologics, Inc.WithdrawnDegenerative Disc Disease | Spondylolisthesis | Retrolisthesis
-
Instituto Tecnologico y de Estudios Superiores...Completed
-
University of California, Los AngelesCompletedPrediabetic StateUnited States
-
Technische Universität DresdenCompletedPeriodontal Disease | Periodontal Attachment LossGermany